Physician profile
Arunpal Sehgal
NPI 1801904099
$4,325.16
in general payments reported to CMS, 2019-2025
22 companies · $984 in 2025
The $984 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $397 · 2021: $431 · 2022: $455 · 2023: $934 · 2024: $593 · 2025: $984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,470 · Education: $40.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,469.86 |
| Education | $40.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,196.96 | 2019-2025 | Ofev, Jascayd |
| Glaxosmithkline, LLC. | $644.75 | 2019-2025 | Nucala, Trelegy Ellipta |
| Abiomed | $465.55 | 2023-2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $316.41 | 2019-2024 | Airsupra |
| Shionogi INC | $284.54 | 2020-2025 | Fetroja |
| Philips North America LLC | $205.20 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $197.86 | 2025 | Lifevest |
| Merck Sharp & Dohme LLC | $188.92 | 2019-2023 | Zerbaxa, Recarbrio |
| Penumbra, INC. | $150.83 | 2025 | Indigo System |
| Insmed, INC. | $136.82 | 2023-2025 | Arikayce |
| Janssen Pharmaceuticals, INC | $79.73 | 2020-2022 | |
| Mylan Specialty L.P. | $77.61 | 2019-2023 | Yupelri |
| Medtronic, INC. | $73.78 | 2025 | Azure Xt Dr Mri Surescan |
| E.R. Squibb & Sons, L.L.C. | $57.78 | 2019-2022 | |
| Melinta Therapeutics, LLC | $50.95 | 2023-2024 | Kimyrsa, Rezzayo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $42.35 | 2022 | |
| Gilead Sciences, INC. | $34.25 | 2023 | Veklury |
| Genzyme Corporation | $34.05 | 2022 | |
| Viiv Healthcare Company | $31.62 | 2021 | |
| Janssen Biotech, INC. | $21.06 | 2022 | |
| Electromed, INC. | $17.28 | 2023 | Smartvest |
| Cmp Pharma, INC. | $16.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arunpal Sehgal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.